Repligen (RGEN) Tops Q1 EPS by 5c, Lowers FY23 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Repligen Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
May 2, 2023 7:30 AM EDTReports first quarter revenue of $182.7 million, with base business growth of 4% as reported and 7% at constant currencyReports first quarter gross margin of 55.2% on both GAAP and adjusted (non-GAAP) basisClosed on acquisition of single-use bag manufacturer FlexBiosys Inc. in April
WALTHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first fiscal quarter ended March 31, 2023. Provided in this press release are financial highlights for the quarter, updates to... More
